Published in Med Decis Making on January 04, 2010
Clarification of Optimal Anticoagulation Through Genetics (COAG) | NCT00839657
Landscape of next-generation sequencing technologies. Anal Chem (2011) 2.58
Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol (2012) 2.11
Personalized medicine: new genomics, old lessons. Hum Genet (2011) 1.85
Personalizing medicine with clinical pharmacogenetics. Genet Med (2011) 1.73
Designing a randomized clinical trial to evaluate personalized medicine: a new approach based on risk prediction. J Natl Cancer Inst (2010) 1.53
Issues surrounding the health economic evaluation of genomic technologies. Pharmacogenomics (2013) 1.45
Parents' attitudes toward pediatric genetic testing for common disease risk. Pediatrics (2011) 1.18
Assessing personalized medicines in Australia: a national framework for reviewing codependent technologies. Med Decis Making (2012) 1.15
Health technology assessment and private payers' coverage of personalized medicine. J Oncol Pract (2011) 1.10
Economic analyses of genetic tests in personalized medicine: clinical utility first, then cost utility. Genet Med (2013) 1.04
Dashboard systems: implementing pharmacometrics from bench to bedside. AAPS J (2014) 0.84
Economic evaluations of personalized medicine: existing challenges and current developments. Pharmgenomics Pers Med (2015) 0.82
Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE). BMC Health Serv Res (2013) 0.80
Personalized medicine and comparative effectiveness research in an era of fixed budgets. EPMA J (2010) 0.80
Getting our priorities straight: a novel framework for stakeholder-informed prioritization of cancer genomics research. Genet Med (2012) 0.78
Economic Evaluation in Stratified Medicine: Methodological Issues and Challenges. Front Pharmacol (2016) 0.78
Characteristics associated with informed consent for genetic studies in the ACCORD trial. Contemp Clin Trials (2013) 0.78
Differences in Weight Loss Between Persons on Standard Balanced vs Nutrigenetic Diets in a Randomized Controlled Trial. Clin Gastroenterol Hepatol (2015) 0.77
Was it worth it? Patients' perspectives on the perceived value of genomic-based individualized medicine. J Community Genet (2016) 0.76
Value of research analysis: an application to drug development. Clin Adv Hematol Oncol (2009) 0.75
Economic Evaluations of Pharmacogenetic Approaches in Infectious Diseases: A Review of Current Approaches and Evaluation of Critical Aspects Affecting their Quality. J Public Health Africa (2013) 0.75
Advanced health biotechnologies in Thailand: redefining policy directions. J Transl Med (2013) 0.75
The Routine Clinical use of Pharmacogenetic Tests: What it Will Require? Pharm Res (2017) 0.75
Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63
The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med (2007) 9.48
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94
Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst (2008) 7.85
Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med (2008) 7.13
National surveillance of emergency department visits for outpatient adverse drug events. JAMA (2006) 6.24
Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation (2007) 5.99
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med (2009) 5.69
Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) (2006) 4.84
Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med (2005) 4.66
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
Economics of new oncology drug development. J Clin Oncol (2007) 3.99
Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov (2007) 3.77
CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther (2007) 3.60
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res (2008) 3.50
A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am J Hum Genet (2008) 3.25
What is the clinical utility of genetic testing? Genet Med (2006) 3.01
Coverage options for promising technologies: Medicare's 'coverage with evidence development'. Health Aff (Millwood) (2006) 2.79
Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics (2006) 2.59
An economic approach to clinical trial design and research priority-setting. Health Econ (1997) 2.54
Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther (2007) 2.54
Warfarin pharmacogenetics. Pharmacotherapy (2008) 2.50
Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J (2006) 2.40
Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet Med (2009) 2.33
Coverage with evidence development: an examination of conceptual and policy issues. Int J Technol Assess Health Care (2007) 2.23
The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics. Clin Pharmacol Ther (2008) 2.21
The path from genome-based research to population health: development of an international public health genomics network. Genet Med (2006) 2.15
Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med (2008) 2.05
Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med (2007) 2.02
Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet Med (2009) 1.94
Challenges of translating genetic tests into clinical and public health practice. Nat Rev Genet (2009) 1.62
Prioritizing future research on off-label prescribing: results of a quantitative evaluation. Pharmacotherapy (2008) 1.58
Value of information on preference heterogeneity and individualized care. Med Decis Making (2007) 1.49
Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther (2007) 1.42
The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes. Diabetes Care (2006) 1.38
Ancillary risk information and pharmacogenetic tests: social and policy implications. Pharmacogenomics J (2007) 1.34
Categorizing genetic tests to identify their ethical, legal, and social implications. Am J Med Genet (2001) 1.34
Personal utility and genomic information: look before you leap. Genet Med (2009) 1.32
Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis. Genet Med (2008) 1.31
Skipping toward personalized molecular medicine. N Engl J Med (2007) 1.30
Saying no isn't NICE - the travails of Britain's National Institute for Health and Clinical Excellence. N Engl J Med (2008) 1.21
Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. Health Aff (Millwood) (2007) 1.12
Coverage with evidence development: ethical issues and policy implications. Med Care (2008) 1.11
Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis (2006) 1.08
Cancer genetics evaluation: barriers to and improvements for referral. Genet Test (2008) 1.01
Linking pharmacogenetics-based diagnostics and drugs for personalized medicine. Health Aff (Millwood) (2006) 0.95
Warfarin and pharmacogenomic testing: the case for restraint. Clin Pharmacol Ther (2008) 0.92
Genetic testing for warfarin therapy initiation. Ann Pharmacother (2008) 0.90
Legal update: living with the Genetic Information Nondiscrimination Act. Genet Med (2008) 0.90
Clinical decision making and the expected value of information. Clin Trials (2007) 0.87
The cost-effectiveness of warfarin pharmacogenomics. J Thromb Haemost (2007) 0.81
Can pharmacoeconomics and outcomes research contribute to the empowerment of women affected by breast cancer? Expert Rev Pharmacoecon Outcomes Res (2008) 0.78
How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach. J Health Serv Res Policy (2007) 0.78
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA (2006) 8.16
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 5.26
Screening for breast cancer. JAMA (2005) 4.56
Global epidemiology of hepatitis B virus. J Clin Gastroenterol (2004) 4.48
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood (2008) 4.02
New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol (2007) 4.01
Content of weblogs written by health professionals. J Gen Intern Med (2008) 3.25
The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med (2010) 2.81
Racial differences in trust in health care providers. Arch Intern Med (2006) 2.80
Strategies for implementing screening for critical congenital heart disease. Pediatrics (2011) 2.72
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2005) 2.70
Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008. Clin Pharmacokinet (2011) 2.67
Warfarin pharmacogenetics. Pharmacotherapy (2008) 2.50
Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Ann Intern Med (2002) 2.43
Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy (2008) 2.34
Delivery of survivorship care by primary care physicians: the perspective of breast cancer patients. J Clin Oncol (2009) 2.23
New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol (2008) 2.23
Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006. J Clin Pharmacol (2008) 2.22
A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics (2010) 2.19
Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study. Lancet Oncol (2012) 2.14
Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis (2007) 2.12
Quantifying the health benefits of genetic tests: the importance of a population perspective. Genet Med (2006) 2.11
Barriers of and facilitators to physician recommendation of colorectal cancer screening. J Gen Intern Med (2007) 2.05
The role of primary androgen deprivation therapy in localized prostate cancer. Eur Urol (2009) 1.97
Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement. J Comp Eff Res (2012) 1.91
Development and testing of the health care system distrust scale. J Gen Intern Med (2004) 1.89
Use of complementary and alternative medicine and prayer among a national sample of cancer survivors compared to other populations without cancer. Complement Ther Med (2006) 1.85
Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy (2010) 1.83
Role of pulse oximetry in examining newborns for congenital heart disease: a scientific statement from the AHA and AAP. Pediatrics (2009) 1.77
An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost (2008) 1.76
Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys (2011) 1.76
Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res (2002) 1.74
Trends in pediatric sickle cell disease-related mortality in the United States, 1983-2002. J Pediatr (2008) 1.73
Role of pulse oximetry in examining newborns for congenital heart disease: a scientific statement from the American Heart Association and American Academy of Pediatrics. Circulation (2009) 1.72
Health care expenditures for infants and young children with Down syndrome in a privately insured population. J Pediatr (2008) 1.70
Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics. Med Decis Making (2013) 1.70
Gender influences treatment and survival in colorectal cancer surgery. Dis Colon Rectum (2009) 1.68
Design, implementation, and first-year outcomes of a value-based drug formulary. J Manag Care Spec Pharm (2015) 1.67
Medical applications of microarray technologies: a regulatory science perspective. Nat Genet (2002) 1.67
Differences in information seeking among breast, prostate, and colorectal cancer patients: results from a population-based survey. Patient Educ Couns (2010) 1.67
Accountable care organizations and health care disparities. JAMA (2011) 1.67
Emergency department visits made by patients with sickle cell disease: a descriptive study, 1999-2007. Am J Prev Med (2010) 1.62
Challenges of translating genetic tests into clinical and public health practice. Nat Rev Genet (2009) 1.62
Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol (2008) 1.61
The association between race and attitudes about predictive genetic testing. Cancer Epidemiol Biomarkers Prev (2004) 1.59
A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Ann Emerg Med (2012) 1.58
Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. J Gastroenterol Hepatol (2007) 1.58
Health care utilization and expenditures for privately and publicly insured children with sickle cell disease in the United States. Pediatr Blood Cancer (2009) 1.54
Development of a revised Health Care System Distrust scale. J Gen Intern Med (2008) 1.53
Trends in in-hospital deaths among hospitalizations with pulmonary embolism. Arch Intern Med (2012) 1.53
A risk-benefit analysis of factor V Leiden testing to improve pregnancy outcomes: a case study of the capabilities of decision modeling in genomics. Genet Med (2012) 1.52
Applying public health strategies to primary immunodeficiency diseases: a potential approach to genetic disorders. MMWR Recomm Rep (2004) 1.52
Racial disparities in stage-specific colorectal cancer mortality: 1960-2005. Am J Public Health (2010) 1.51
Pharmacogenetics--tailoring treatment for the outliers. N Engl J Med (2009) 1.50
Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations. Genet Test (2008) 1.46
Economic outcome of cardiac CT-based evaluation and standard of care for suspected acute coronary syndrome in the emergency department: a decision analytic model. Acad Radiol (2011) 1.45
The timing of elective colectomy in diverticulitis: a decision analysis. J Am Coll Surg (2004) 1.45
The geographic accessibility of retail clinics for underserved populations. Arch Intern Med (2009) 1.44
Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis. Pharmacogenet Genomics (2006) 1.44
Summary workshop report: biopharmaceutics classification system--implementation challenges and extension opportunities. J Pharm Sci (2004) 1.43
Optimizing CAD diagnosis in China with CT angiography. J Cardiovasc Comput Tomogr (2009) 1.43
Symptom burden among cancer survivors: impact of age and comorbidity. J Am Board Fam Med (2007) 1.43
Professional Fee Ratios for US Hospital Discharge Data. Med Care (2015) 1.42
Prostate-specific antigen surveillance among men with clinically localized prostate cancer who do not receive initial treatment. Urology (2011) 1.40
Physician social networks and variation in prostate cancer treatment in three cities. Health Serv Res (2011) 1.40
The effect of numerical statements of risk on trust and comfort with hypothetical physician risk communication. Med Decis Making (2004) 1.39
Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet Med (2012) 1.39
Cancer information scanning and seeking in the general population. J Health Commun (2010) 1.36
De qi: Chinese acupuncture patients' experiences and beliefs regarding acupuncture needling sensation--an exploratory survey. Acupunct Med (2007) 1.36
Health care expenditures of children and adults with spina bifida in a privately insured U.S. population. Birth Defects Res A Clin Mol Teratol (2007) 1.32
Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support. BMC Bioinformatics (2010) 1.32
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst (2010) 1.30
Cost-effectiveness of routine screening for critical congenital heart disease in US newborns. Pediatrics (2013) 1.28
Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther (2002) 1.28
Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med (2005) 1.27
Postoperative mortality after esophagectomy for cancer: development of a preoperative risk prediction model. Ann Surg Oncol (2008) 1.27
Racial and ethnic disparities in awareness of genetic testing for cancer risk. Am J Prev Med (2009) 1.26
Issues related to the diagnosis and treatment of autism spectrum disorders. Ment Retard Dev Disabil Res Rev (2007) 1.26
Cancer and communication in the health care setting: experiences of older Vietnamese immigrants, a qualitative study. J Gen Intern Med (2007) 1.25
Decrease in racial disparities in the staging evaluation for prostate cancer after publication of staging guidelines. J Urol (2007) 1.24
National Cancer Institute designation predicts improved outcomes in colorectal cancer surgery. Ann Surg (2008) 1.20
Measures of follow-up in early hearing detection and intervention programs: a need for standardization. Am J Audiol (2008) 1.20
Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective. Biomark Med (2008) 1.20
Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics (2010) 1.19
The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med (2004) 1.19
The association between knowledge and attitudes about genetic testing for cancer risk in the United States. J Health Commun (2005) 1.18
A cost-effectiveness analysis of intraoperative cholangiography in the prevention of bile duct injury during laparoscopic cholecystectomy. J Am Coll Surg (2003) 1.18
Nonfinancial barriers and access to care for U.S. adults. Health Serv Res (2011) 1.18
Prioritization in comparative effectiveness research: the CANCERGEN Experience. Med Care (2012) 1.17
Children with orofacial clefts: health-care use and costs among a privately insured population. Public Health Rep (2009) 1.16
Return of incidental findings in genomic medicine: measuring what patients value--development of an instrument to measure preferences for information from next-generation testing (IMPRINT). Genet Med (2013) 1.16
The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health (2008) 1.16
Sickle cell disease-related pediatric medical expenditures in the U.S. Am J Prev Med (2010) 1.16
Hospitalizations, costs, and mortality among infants with critical congenital heart disease: how important is timely detection? Birth Defects Res A Clin Mol Teratol (2013) 1.15
Acupuncture for hot flashes: decision making by breast cancer survivors. J Am Board Fam Med (2012) 1.15
Racial differences in prostate cancer treatment outcomes: a systematic review. Cancer Nurs (2005) 1.15